Peptide Protocol
Peptide Protocol
 App Store

MK-677: the complete guide

MK-677 (ibutamoren) is an orally active, non-peptide ghrelin receptor agonist studied for sustained elevation of GH and IGF-1. Unlike injectable GHRPs, it is taken by mouth.

Written by Peptide Protocol Editorial Medically reviewed per our review process Last reviewed
ClassOral ghrelin mimetic / GHSR agonist
Half-lifeApproximately 24 hours (oral)
Typical dose10–25 mg orally once daily
CategoryGrowth hormone axis
Research useGH/IGF-1 research, body composition, oral alternative
FDA statusNot FDA approved. Investigational; research use only.

How MK-677 works

MK-677 mimics ghrelin at the GHSR-1a receptor, stimulating pulsatile GH release and raising 24-hour IGF-1 levels with once-daily oral dosing.

Typical MK-677 dosage

Commonly reported research ranges: 10–25 mg orally once daily.

Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.

Administration

MK-677 is taken orally — no reconstitution is required. Follow the manufacturer's guidance for liquid or capsule dosing.

Half-life and administration frequency

Approximately 24 hours (oral).

This half-life informs how often MK-677 is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.

Reported side effects

This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.

Common MK-677 stacks

Storage and handling

Oral compound — store capsules/liquid per manufacturer. Typically room temperature, away from light.

FDA and regulatory status

Not FDA approved. Investigational; research use only.

MK-677 clinical trials and evidence

For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.

Track your MK-677 protocol on iPhone

Peptide Protocol logs every dose, calculates reconstitution for you, and keeps your full protocol on one calm screen.

See the app →

Frequently asked questions

What is MK-677?

MK-677 (ibutamoren) is an orally active, non-peptide ghrelin receptor agonist studied for sustained elevation of GH and IGF-1. Unlike injectable GHRPs, it is taken by mouth.

How does MK-677 work?

MK-677 mimics ghrelin at the GHSR-1a receptor, stimulating pulsatile GH release and raising 24-hour IGF-1 levels with once-daily oral dosing.

What is a typical MK-677 dose?

Commonly reported ranges are 10–25 mg orally once daily. This is research information, not a recommendation — dosing should be individualized under clinical guidance.

What is the half-life of MK-677?

Approximately 24 hours (oral). This influences how often it is taken.

Does MK-677 require reconstitution?

MK-677 is not handled as a standard lyophilized injectable reconstitution page in this database. Follow the manufacturer, study protocol, or clinician instructions for the specific formulation.

What are the side effects of MK-677?

Increased appetite (significant); Water retention; Lethargy (early dosing); Elevated fasting glucose; Possible edema.

Is MK-677 FDA approved?

Not FDA approved. Investigational; research use only.

Are there clinical trials for MK-677?

Registered or published clinical-trial sources for MK-677 are listed in the references section below. Evidence depth varies widely by compound, so check the cited trial registries and primary literature before relying on any claim.

References

  1. MK-677 / Ibutamoren literature (PubMed) — National Library of Medicine. Primary studies on oral ghrelin mimetic MK-677
  2. Nass et al. — Effects of an oral ghrelin mimetic on body composition — PubMed. Landmark 2-year trial in older adults — lean-mass and IGF-1 outcomes
  3. MK-677 clinical trial records — ClinicalTrials.gov. Registered human studies across multiple indications

Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.

Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.